Overcoming the Personalized Medicine Bottleneck:
Delivering the Perfect Diagnostic Test For Clinical Investigations

Tuesday, October 6 | 12pm GMT, 1pm CET | 1.5-hour presentation & interactive panel,
30 minutes consultation

Engage News & Brews
hosted by...


This online Covance and Illumina Engager is part of an exclusive event series providing leaders in pharma and biotech an opportunity to explore the latest insights and innovations facilitating the advancement of precision medicine.

These popular events have been adapted to a virtual format, so you can forge connections with key company and industry thought leaders and learn about diagnostic advances that have the potential to expedite end-to-end drug development, from the comfort of your own home.

Register your interest today not to miss this bespoke, interactive and intimate session.

Join Covance and Illumina for an exploration into:

Overcoming the Personalized Medicine Bottleneck: Delivering the Perfect Diagnostic Test For Clinical Investigations

Personalized approaches to cancer care are offering hope for patients to see more timely and targeted interventions and improved disease outcomes.


With innovations in technologies a big facilitator of progress in this space, diagnostic improvements are offering drug developers the capacity to stratify patient populations and guide effective clinical decision making.

Despite the attractive promise of precision oncology, the fast paced and ever-changing clinical development environment presents significant challenges for targeted treatment development. Where is clarity needed to allow pharma to pursue biomarker strategies to see clinical and commercial success?

Address this question and more alongside your drug development peers throughout this interactive online event. Join to be equipped with the latest actionable insight you can take away to your teams to accelerate innovative new biomarkers into clinical adoption, improve testing validation and fine-tune your clinical trial design to see improved experience and engagement.

Key Topics Include:  

  • Building standardised technological support to enable the delivery of efficient biomarker strategies in high growth fast-paced fields
  • Solutions to accelerate the clinical adoption and validation of tests from RUO towards IVD diagnostics
  • Enabling precision patient management in clinical trial programs via patient-centric approaches to cancer treatment
  • Future thinking approaches to care in oncology: Pre-validating tests to accelerate innovative biomarkers into clinical trial cohorts at scale workflows
  • Assessing data complexity and interpretation in centralised vs decentralised testing to better inform decision-making and streamline workflows

Following a live Q&A, feel free to stay and mingle with key executives from Covance and Illumina, as well as your precision oncology peers to converse and learn how others are addressing today’s most pressing industry challenges.

Who should attend?

This is an event for senior executives from drug development organizations looking to refine trial design, increase identification of patient responders and accelerate delivery of the next generation of targeted therapies in areas of high unmet need.

Should you have any questions, please reach out to dominic.allen@hansonwade.com and we will be in touch!

Your Speakers

Mark Roberts

Mark Roberts

Senior Director, Diagnostics Development


Volker Liebenberg

Volker Liebenberg

Director, Medical Affairs EMEA